Systemic Therapies for Pediatric Alopecia Areata

Area of Science:

• Dermatology
• Pediatric Autoimmune Disorders
• Hair Loss Research

Background:

• Alopecia areata (AA) is an autoimmune condition causing hair loss, frequently impacting children.
• Mild cases may resolve spontaneously or with topical treatments, but extensive AA necessitates systemic therapies.
• Evidence for systemic treatments in pediatric AA is scarce, primarily from case reports and series.

Purpose of the Study:

• To review existing literature on systemic treatment options for pediatric alopecia areata.
• To evaluate the efficacy and evidence base for various systemic therapies in children with AA.

Main Methods:

• A narrative review of published literature on systemic treatments for pediatric alopecia areata.
• Analysis of case reports, case series, and limited clinical trial data.

Main Results:

• Janus kinase (JAK) inhibitors are the only medication class with systematic data supporting their use in pediatric AA.
• Oral minoxidil shows increasing reports of benefit, particularly as an add-on therapy.
• Dupilumab may benefit patients with AA and co-existing atopy; systemic corticosteroids offer temporary improvement but have significant risks and limited sustained efficacy.

Conclusions:

• High-quality evidence for systemic treatments in pediatric alopecia areata is limited.
• JAK inhibitors represent a promising therapeutic class, supported by systematic data.
• Oral minoxidil and dupilumab warrant further investigation, while traditional immunomodulators lack substantial supporting literature.